Prostatype Genomics Ab Stock Total Debt
| PROGEN Stock | SEK 5.45 0.10 1.80% |
Prostatype Genomics AB fundamentals help investors to digest information that contributes to Prostatype Genomics' financial success or failures. It also enables traders to predict the movement of Prostatype Stock. The fundamental analysis module provides a way to measure Prostatype Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prostatype Genomics stock.
Prostatype |
Prostatype Genomics AB Company Total Debt Analysis
Prostatype Genomics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Prostatype Genomics Total Debt | 866.67 K |
Most of Prostatype Genomics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prostatype Genomics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Prostatype Genomics AB has a Total Debt of 866.67 K. This is 99.97% lower than that of the Healthcare sector and 99.91% lower than that of the Diagnostics & Research industry. The total debt for all Sweden stocks is 99.98% higher than that of the company.
Prostatype Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prostatype Genomics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prostatype Genomics could also be used in its relative valuation, which is a method of valuing Prostatype Genomics by comparing valuation metrics of similar companies.Prostatype Genomics is currently under evaluation in total debt category among its peers.
Prostatype Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (23.61) % | |||
| Current Valuation | 20.62 M | |||
| Shares Outstanding | 22.86 M | |||
| Shares Owned By Insiders | 1.00 % | |||
| Shares Owned By Institutions | 13.47 % | |||
| Price To Book | 1.14 X | |||
| Price To Sales | 34.59 X | |||
| Revenue | 10 K | |||
| Gross Profit | (5.98 M) | |||
| EBITDA | (15.46 M) | |||
| Net Income | (15.63 M) | |||
| Cash And Equivalents | 7.66 M | |||
| Cash Per Share | 0.58 X | |||
| Total Debt | 866.67 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.10 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (16.08 M) | |||
| Earnings Per Share | (1.22) X | |||
| Target Price | 21.02 | |||
| Beta | 1.22 | |||
| Market Capitalization | 42.29 M | |||
| Total Asset | 40.2 M | |||
| Z Score | 28.8 | |||
| Net Asset | 40.2 M |
About Prostatype Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prostatype Genomics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prostatype Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prostatype Genomics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Prostatype Stock
Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.